Inotrem announces FDA clearance of Investigational New Drug (IND) for the phase IIB ASTONISH trial in septic shock patients to demonstrate nangibotide efficacy
August 6, 2019
Paris (France). August 6. 2019. Inotrem S.A., a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, announced today the U.S. Food and Drug Administration